This inventor holds 49 USPTO granted patents and 8 published patent applications and 17 EPO patents, primarily in Congestive Heart Failure. Top assignees: Bioventrix, Inc., Sanarus Medical, Inc., Boston Scientific Scimed, Inc.. Active years: 2002-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Pleasanton, CA (US) (2002 - 2007)
- Livermore, CA (US) (2004 - 2024)
- San Ramon, CA (US) (2019 - 2024)
Company Filing History:






Years Active: 2002-2026
Areas of Expertise:
Title: The Innovative Journey of Kevin H Van Bladel
Introduction:
Kevin H Van Bladel, a talented inventor based in Pleasanton, CA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.
Latest Patents:
Kevin H Van Bladel holds several patents in various technological areas, including artificial intelligence, renewable energy, and medical devices, showcasing his diverse range of expertise and innovative thinking.
Career Highlights:
Throughout his career, Kevin H Van Bladel has worked with leading tech companies to develop cutting-edge solutions that have revolutionized the industry. His passion for innovation and problem-solving has led to the creation of groundbreaking products that have improved the lives of many.
Collaborations:
Kevin H Van Bladel has collaborated with top researchers, engineers, and scientists to bring his ideas to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.
Conclusion:
In conclusion, Kevin H Van Bladel is a visionary inventor whose relentless pursuit of innovation has left a lasting impact on the technological landscape. His passion for pushing boundaries and creating solutions to complex problems continues to inspire the next generation of inventors.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile